AUTL Autolus Therapeutics (AUTL) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001730463
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
36
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $47.0K priced
What the filings say about AUTL
Insiders, 180 days
-$15.7K net sold
1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$15.7K
1 notice
Autolus Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Autolus Therapeutics plc insiders sold a net $15.7K of stock across 1 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 50.5% of the 13,287 shares held after it.
- No other insider sold within 30 days.
- 36 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: U.S. CCO & Country Gen Manager Piccina Cintia sold about $15.7K of AUTL on Sep 2, 2026, the largest insider sale at the company on our record; 36 funds added in the latest 13F quarter.1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$15.7K over 180 days
-$15.7K over 90 days
more than 60% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
36 funds bought in last quarter
below 59% of Pharma & Biotech
Revenue
+644.9% year over year
more than 95% of Pharma & Biotech
Margin
-381.4% net margin
below 75% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
8.2% of the float short (float per yahoo 2026-10-26) · 5.7 days to cover · settled 2026-09-30
below 59% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch AUTL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+3.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns AUTL: institutional holders (13F)
13F holdings, latest reported quarter
33,621,487 sh
$53.8M
20,485,611 sh
$32.8M
16,640,720 sh
$26.6M
15,000,000 sh
$24.0M
9,500,000 sh
$15.2M
Congress trades in AUTL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
AUTL planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Piccina Cintia
Filed 2026-09-02
$15.7K
AUTL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$84.0K position · as of 2026-05-31
0.4%
Invesco Nasdaq Biotechnology ETF
$19.8K position · as of 2026-05-31
0.0%
iShares Biotechnology ETF
$2.3M position · as of 2026-06-30
0.0%
ProShares Ultra Nasdaq Biotechnology
$13.9K position · as of 2026-05-31
0.0%
State Street(R) SPDR(R) S&P(R) International Small Cap ETF
$135.1K position · as of 2026-06-30
0.0%
ActivePassive International Equity ETF
$42.5K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $15.7K sold by insiders over 180 days, 36 funds added last quarter, $15.7K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
AUTL financials
Revenue growth
+644.9%
XBRL, annual
Net margin
-381.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$117.4M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AUTL
| FY Dec 2025 | $75.4M |
| FY Dec 2024 | $10.1M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $45.7M |
| Mar 2026 | $26.2M |
| Dec 2025 | $24.3M |
| Sep 2025 | $21.2M |
| Jun 2025 | $20.9M |
| Mar 2025 | $9.0M |
| Dec 2024 | $29.0K |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
-238.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM AUTL
| FY Dec 2025 | -381.4% |
| FY Dec 2024 | -2,180% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -85.6% |
| Mar 2026 | -273.1% |
| Dec 2025 | -371.9% |
| Sep 2025 | -373.3% |
| Jun 2025 | -229.0% |
| Mar 2025 | -781.1% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$232.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM AUTL
| FY Dec 2025 | -$302.6M |
| FY Dec 2024 | -$228.3M |
| FY Dec 2023 | -$156.6M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -$145.0M |
| Jun 2026 | -$26.0M |
| Mar 2026 | -$68.0M |
| Dec 2025 | -$66.4M |
| Sep 2025 | -$72.3M |
| Jun 2025 | -$80.1M |
| Mar 2025 | -$83.8M |
| Dec 2024 | -$49.0M |
| Sep 2024 | -$86.3M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2019-12-31 (79 months older than the period end); equity 2026-06-30
Debt to equity AUTL
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt AUTL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-133.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity AUTL
| FY Dec 2025 | -95.0% |
| FY Dec 2024 | -81.9% |
| FY Dec 2023 | -101.6% |
| FY Dec 2022 | -48.6% |
| FY Dec 2021 | -49.6% |
| Jun 2026 | -133.0% |
| Mar 2026 | -120.4% |
| Dec 2025 | -95.0% |
| Sep 2025 | -60.6% |
| Jun 2025 | -52.1% |
| Mar 2025 | -50.0% |
| Dec 2024 | -81.9% |
| Sep 2024 | -82.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-46.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AUTL
| FY Dec 2025 | -41.9% |
| FY Dec 2024 | -38.1% |
| FY Dec 2023 | -48.1% |
| FY Dec 2022 | -33.2% |
| FY Dec 2021 | -42.3% |
| Jun 2026 | -46.1% |
| Mar 2026 | -45.4% |
| Dec 2025 | -41.9% |
| Sep 2025 | -30.2% |
| Jun 2025 | -28.9% |
| Mar 2025 | -28.9% |
| Dec 2024 | -38.1% |
| Sep 2024 | -43.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital AUTL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-45.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed AUTL
| FY Dec 2025 | -43.7% |
| FY Dec 2024 | -45.9% |
| FY Dec 2023 | -46.4% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -53.7% |
| Jun 2026 | -45.9% |
| Mar 2026 | -46.3% |
| Dec 2025 | -43.7% |
| Sep 2025 | -40.5% |
| Jun 2025 | -36.9% |
| Mar 2025 | -34.9% |
| Dec 2024 | -45.9% |
| Sep 2024 | -38.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing AUTL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$241.1M
market value at close 2026-10-27 on 2026-08-10 shares, plus long-term debt only, 2019-12-31 (79 months older than the period end), minus cash 2026-06-30
Enterprise value AUTL
| FY Dec 2025 | $425.5M |
| FY Dec 2024 | $398.0M |
| FY Dec 2023 | $880.9M |
| FY Dec 2022 | -$53.6M |
| FY Dec 2021 | $161.5M |
| Jun 2026 | $254.4M |
| Mar 2026 | $236.4M |
| Dec 2025 | $425.5M |
| Sep 2025 | $347.7M |
| Jun 2025 | $483.0M |
| Mar 2025 | $316.7M |
| Dec 2024 | $398.0M |
| Sep 2024 | $308.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-56.4%
TTM free cash flow over market value at close 2026-10-27
FCF yield AUTL
| FY Dec 2025 | -57.1% |
| FY Dec 2024 | -36.5% |
| FY Dec 2023 | -14.0% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -30.7% |
| Jun 2026 | -54.7% |
| Mar 2026 | -78.1% |
| Dec 2025 | -57.1% |
| Sep 2025 | -65.7% |
| Jun 2025 | -49.3% |
| Mar 2025 | -65.7% |
| Dec 2024 | -36.5% |
| Sep 2024 | -21.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing AUTL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $75.4M | $10.1M | $1.7M | n/a |
| Operating income | -$270.5M | -$241.4M | -$179.7M | -$143.4M |
| Net income | -$287.5M | -$220.7M | -$208.4M | -$148.8M |
| EPS (diluted) | -1.08 | -0.86 | -1.20 | -1.57 |
| Operating cash flow | -$283.6M | -$206.3M | -$145.6M | -$112.3M |
| Cash | $104.1M | $227.4M | $239.6M | $382.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
AUTL Stock Sonar score 6/7 axes
Find similar shapesCompareAUTL ranks highest on financial health (99th percentile) and growth (95th), and lowest on insider conviction (30th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
AUTL filings, in plain words
Are Autolus Therapeutics insiders buying or selling AUTL?
In the 180 days to 2026-10-28, Autolus Therapeutics insiders were net sellers, a net $15.7K across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of AUTL?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $15.7K of stock; the latest, by Piccina Cintia, was filed 2026-09-02.
Read the full summary
In the 180 days to 2026-10-28, Autolus Therapeutics insiders were net sellers of AUTL, a net $15.7K across purchases and sales reported on Form 4 by 1 seller. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $15.7K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
